Pharmaceutical Intermediate CDMO Market Research Report
商品番号 : SMB-81617
| 出版社 | Market Research Future |
| 出版年月 | 2025年7月 |
| ページ数 | 146 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
医薬品中間体CDMO市場調査レポート : 中間体の種類[医薬品有効成分（API）、賦形剤および添加剤、生物製剤中間体、ヌクレオチド中間体]、医薬品の種類別（ジェネリック医薬品、ブランド医薬品）、用途別（腫瘍学、心血管疾患、中枢神経系および神経疾患、感染症）、地域別（北米、ヨーロッパ、南米、中東およびアフリカ、アジア太平洋）2035年までの予測
Market Overview
From 2024 to 2035, the global pharmaceutical intermediate CDMO market is projected to increase at a compound annual growth rate (CAGR) of 7.4% to reach USD 346,744.3 million. In 2024, the market was valued at USD 161,798.9 million.
2024年から2035年にかけて、世界の医薬品中間体CDMO市場は年平均成長率（CAGR）7.4%で成長し、3,467億4,430万米ドルに達すると予測されています。2024年には、市場規模は1,617億9,890万米ドルに達しました。
The global Pharmaceutical Intermediate CDMO (Contract Development and Manufacturing Organization) market is witnessing strong growth driven by several factors. Pharmaceutical companies are increasingly outsourcing intermediate manufacturing to CDMOs to streamline operations and cut costs. The rising demand for generic drugs and biosimilars, particularly in developing regions, is significantly boosting market expansion. Additionally, rapid technological advancements in intermediate synthesis and the increasing complexity of drug molecules are encouraging companies to rely on specialized CDMO services. Emerging markets are also playing a vital role in global growth due to favorable government policies and rising healthcare infrastructure.
世界の医薬品中間体CDMO（受託開発製造機関）市場は、いくつかの要因に牽引され、力強い成長を遂げています。製薬会社は、業務の効率化とコスト削減のため、中間体製造をCDMOに委託するケースが増えています。特に発展途上地域におけるジェネリック医薬品とバイオシミラーの需要の高まりが、市場拡大を大きく後押ししています。さらに、中間体合成における急速な技術進歩と医薬品分子の複雑化も、企業が専門的なCDMOサービスへの依存を促しています。新興市場も、政府の優遇政策と医療インフラの整備により、世界的な成長において重要な役割を果たしています。
The market faces restraints such as stringent regulatory frameworks and complex approval processes, which can delay product timelines. High operational and capital costs, IP protection concerns, and raw material shortages also pose challenges. Moreover, there’s a lack of skilled expertise in niche chemistries. Nonetheless, opportunities lie in forming strategic collaborations with biotech firms and capitalizing on the rising trend of personalized medicine.
Market Segmentations
Global Pharmaceutical intermediate CDMO market has been segmented by type of intermediate, includes active pharmaceutical ingredients (APIS), excipients and additives, biologics intermediates, nucleotide intermediates.
In terms of drug type, the global market is divided into generic drugs, branded drug.
Based on the application types, global pharmaceutical intermediate CDMO market comprises oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.
The market is categorized into region, includes North America, Europe, South America, Middle East and Africa, and Asia Pacific.
Regional Insights
North America leads the global pharmaceutical intermediate CDMO market, with the U.S. at the forefront due to its advanced technology, substantial R&D funding, and strict FDA regulations. Canada’s growing biopharma industry also adds to the region’s strength.
In Europe, the market caters to both local and international pharmaceutical firms, focusing on innovation, compliance, and high-quality solutions for complex chemical syntheses. The adoption of eco-friendly practices and support for circular economy initiatives are transforming manufacturing approaches.
Asia Pacific stands out as the fastest-growing region, mainly fueled by China and India’s affordable production capacity and expanding biopharma sectors. The region offers large-scale manufacturing capabilities with integrated facilities and cost efficiency.
Latin American CDMOs face challenges due to inconsistent regulations, though regional collaborations are pushing for harmonization. The region benefits from geographical proximity to North America and a cost-effective labor force, although infrastructural shortcomings have limited rapid expansion.
In the Middle East and Africa, CDMOs are primarily engaged in producing intermediates for generics and essential medications, mostly targeting local markets and nearby regions. Its strategic location between Europe and Asia enhances its relevance in global supply chains, giving the region potential to grow into a critical link in pharmaceutical logistics and production networks.
Major Players
Raghava Life Sciences Pvt LTD., Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Thermo Fisher Scientific, Cambrex Corporation, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the major competitors of the global pharmaceutical intermediate CDMO market.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY …………………………………………… 18
1.1 MARKET OVERVIEW: ………………. 19
1.2 MARKET SEGMENTATION ……… 19
1.3 COMPETITIVE LANDSCAPE …….. 19
1.4 FUTURE OUTLOOK ……………………. 20
2 MARKET INTRODUCTION ……………………………………….. 22
2.1 DEFINITION ……………………………….. 22
2.2 SCOPE OF THE STUDY ……………… 22
2.3 RESEARCH OBJECTIVE ……………. 22
2.4 MARKET STRUCTURE ……………… 23
3 RESEARCH METHODOLOGY …………………………………… 24
3.1 OVERVIEW …………………………………. 24
3.2 DATA FLOW ……………………………….. 26
3.2.1 Data Mining Process ……….. 26
3.3 PURCHASED DATABASE: …………. 27
3.4 SECONDARY SOURCES: ……………. 28
3.4.1 Secondary Research Data Flow: ………………………………………………… 29
3.5 PRIMARY RESEARCH: ………………. 30
3.5.1 Primary Research DATA FLOW: ………………………………………………… 31
3.5.2 Primary Research: Number of Interviews conducted ……………………… 32
3.5.3 Primary Research: Regional Coverage ………………………………………… 32
3.6 APPROACHES FOR MARKET END USER ESTIMATION: …………….. 33
3.6.1 Revenue Analysis Approach …………………………………………………….. 33
3.6.2 Data forecasting …………….. 34
3.6.3 Data Forecasting Technique …………………………………………………….. 34
3.7 DATA MODELING ………………………. 35
3.7.1 microeconomic factor analysis: ………………………………………………… 35
3.7.2 Data modeling: ………………. 36
3.8 TEAMS AND ANALYST CONTRIBUTION ……………………………………… 37
4 MARKET DYNAMICS ……………………………………………….. 39
4.1 INTRODUCTION …………………………. 39
4.2 DRIVERS ……………………………………… 40
4.2.1 Increasing Outsourcing by Pharmaceutical Companies ………………….. 40
4.2.2 Rising Demand for Generic Drugs and Biosimilars ………………………… 40
4.2.3 Technological Advancements in Intermediate Synthesis ………………… 40
4.2.4 Growing Complexity of Drug Molecules ………………………………………. 40
4.2.5 Expansion in Emerging Markets ………………………………………………… 40
4.3 RESTRAINTS ……………………………… 42
4.3.1 Stringent Regulatory Compliance and Complex Approval Processes …. 42
4.3.2 High Operational and Capital Expenditure Costs …………………………… 42
4.3.3 Property (IP) Risks and Confidentiality Concerns ………………………….. 42
4.3.4 Supply Chain Disruptions and Raw Material Shortages …………………… 42
4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry …… 42
4.4 OPPORTUNITY …………………………… 44
4.4.1 Strategic Partnerships with Biotech Firms …………………………………… 44
4.4.2 Focus on Personalized Medicine Solutions …………………………………. 44
4.5 IMPACT ANALYSIS OF COVID – 19 ………………………………………………… 45
5 MARKET FACTOR ANALYSIS …………………………………… 46
5.1 SUPPLY CHAIN ANALYSIS ……… 46
5.1.1 Raw Material Sourcing & Procurement ……………………………………….. 46
5.1.2 Research, Development, & Process Optimization ………………………….. 46
5.1.3 Manufacturing & Quality Control ……………………………………………….. 47
5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery …. 47
5.2 PORTER’S FIVE FORCES MODEL ……………………………………………………. 48
5.2.1 Threat of New Entrants (Low to Moderate) ………………………………….. 48
5.2.2 Bargaining Power of Suppliers (Moderate) ………………………………….. 48
5.2.3 Threat of Substitutes (Low to Moderate) …………………………………….. 49
5.2.4 Bargaining Power of Buyers (High) ……………………………………………. 49
5.2.5 Intensity of Rivalry (High) …. 49
6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE …. 51
6.1 INTRODUCTION …………………………. 51
6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS) …………………….. 52
6.3 EXCIPIENTS & ADDITIVES ………. 52
7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE ……………….. 53
7.1 INTRODUCTION …………………………. 53
7.2 GENERIC DRUGS ………………………… 54
7.3 BRANDED DRUGS ………………………. 54
8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION …………….. 55
8.1 INTRODUCTION …………………………. 55
8.2 ONCOLOGY …………………………………. 56
8.3 CARDIOVASCULAR DISEASES … 56
8.4 CNS & NEUROLOGICAL DISORDERS ……………………………………………….. 56
8.5 INFECTIOUS DISEASES …………….. 57
8.6 OTHERS ………………………………………. 57
9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION ……………………… 58
9.1 GLOBAL ………………………………………. 58
9.2 NORTH AMERICA ……………………… 59
9.2.1 USA …………………………….. 63
9.2.2 CANADA ………………………. 64
9.3 EUROPE ………………………………………. 65
9.3.1 united kingdom………………. 69
9.3.2 germany ……………………….. 71
9.3.3 france ………………………….. 72
9.3.4 italy …………………………….. 73
9.3.5 spain …………………………… 74
9.3.6 RUSSIA ………………………… 75
9.3.7 rest of europe ………………… 76
9.4 ASIA PACIFIC …………………………….. 77
9.4.1 china……………………………. 82
9.4.2 South Korea ………………….. 83
9.4.3 indiA ……………………………. 84
9.4.4 Japan ………………………….. 85
9.4.5 indonesia ……………………… 86
9.4.6 malaysia ………………………. 87
9.4.7 thailand ………………………… 88
9.4.8 rest of asia pacific ………….. 89
9.5 SOUTH AMERICA ……………………… 90
9.5.1 Mexico …………………………. 95
9.5.2 Brazil …………………………… 96
9.5.3 argentina………………………. 97
9.5.4 rest of south america ………. 98
9.6 MIDDEL EAST AND AFRICA …….. 99
9.6.1 gcc countries ………………… 105
9.6.2 south africa …………………… 106
9.6.3 rest of middle east & africa ……………………………………………………… 107
10 COMPETITIVE LANDSCAPE …………………………………….. 108
10.1 INTRODUCTION …………………………. 108
10.2 MARKET SHARE ANALYSIS, 2024SS ……………………………………………. 109
10.3 COMPETITOR DASHBOARD……… 110
11 COMPANY PROFILES ……………………………………………… 111
11.1 RAGHAVA LIFE SCIENCES PVT LTD ……………………………………………… 111
11.1.1 COMPANY OVERVIEW ……… 111
11.1.2 Key Development ……………. 112
11.1.3 SWOT ANALYSIS ……………. 112
11.1.4 Key Strategy ………………….. 113
11.2 ACTYLIS ……………………………………… 114
11.2.1 COMPANY OVERVIEW ……… 114
11.2.2 PRODUCT OFFERED ………… 115
11.2.3 Key Development ……………. 115
11.2.4 SWOT ANALYSIS ……………. 116
11.2.5 Key Strategy ………………….. 116
11.3 CHIRACON GMBH ……………………… 117
11.3.1 COMPANY OVERVIEW ……… 117
11.3.2 PRODUCT OFFERED ………… 118
11.3.3 SWOT ANALYSIS ……………. 118
11.3.4 Key Strategy ………………….. 119
11.4 CODEXIS, INC. …………………………….. 120
11.4.1 COMPANY OVERVIEW ……… 120
11.4.2 PRODUCT OFFERED ………… 121
11.4.3 Key Development ……………. 121
11.4.4 SWOT ANALYSIS ……………. 122
11.4.5 financial analysis ……………. 123
11.4.6 Key Strategy ………………….. 123
11.5 ARKEMA S.A. …………………………….. 124
11.5.1 COMPANY OVERVIEW ……… 124
11.5.2 PRODUCT OFFERED ………… 125
11.5.3 SWOT ANALYSIS ……………. 125
11.5.4 financial analysis ……………. 126
11.5.5 Key Strategy ………………….. 126
11.6 LONZA GROUP AG ……………………… 127
11.6.1 COMPANY OVERVIEW ……… 127
11.6.2 PRODUCT OFFERED ………… 128
11.6.3 Key Development ……………. 128
11.6.4 SWOT ANALYSIS ……………. 129
11.6.5 financial analysis ……………. 130
11.6.6 Key Strategy ………………….. 130
11.7 THERMO FISHER SCIENTIFIC (PATHEON) …………………………………… 131
11.7.1 COMPANY OVERVIEW ……… 131
11.7.2 PRODUCT OFFERED ………… 132
11.7.3 Key Development ……………. 132
11.7.4 SWOT ANALYSIS ……………. 133
11.7.5 financial analysis ……………. 134
11.7.6 Key Strategy ………………….. 134
11.8 CAMBREX CORPORATION ……….. 135
11.8.1 COMPANY OVERVIEW ……… 135
11.8.2 PRODUCT OFFERED ………… 136
11.8.3 Key Development ……………. 136
11.8.4 SWOT ANALYSIS ……………. 137
11.8.5 Key Strategy ………………….. 137
11.9 CATALENT, INC. ………………………… 138
11.9.1 COMPANY OVERVIEW ……… 138
11.9.2 PRODUCT OFFERED ………… 139
11.9.3 Key Development ……………. 139
11.9.4 SWOT ANALYSIS ……………. 140
11.9.5 financial analysis ……………. 141
11.9.6 Key Strategy ………………….. 141
11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD ………………………. 142
11.10.1 COMPANY OVERVIEW ……… 142
11.10.2 PRODUCT OFFERED ………… 143
11.10.3 Key Development ……………. 143
11.10.4 SWOT ANALYSIS ……………. 144
11.10.5 financial analysis ……………. 145
11.10.6 Key Strategy ………………….. 145
LIST OF TABLES
TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 51
TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 53
TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 55
TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION) 58
TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 60
TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 60
TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 61
TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 62
TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 63
TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 63
TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 63
TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 64
TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 64
TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 64
TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 66
TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 67
TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 67
TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 68
TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 69
TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 69
TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 70
TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 71
TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 71
TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 71
TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 72
TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 72
TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 72
TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 73
TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 73
TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 73
TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 74
TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 74
TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 74
TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 75
TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 75
TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 75
TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 76
TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 76
TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 76
TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 78
TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 79
TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 80
TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 81
TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 82
TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 82
TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 82
TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 83
TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 83
TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 83
TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 84
TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 84
TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 84
TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 85
TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 85
TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 85
TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 86
TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 86
TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 86
TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 87
TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 87
TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 87
TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 88
TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 88
TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 88
TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 89
TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 89
TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 89
TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION) 91
TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 91
TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 92
TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 93
TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 95
TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 95
TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 95
TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 96
TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 96
TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 96
TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 97
TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 97
TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 97
TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035
(USD MILLION) 98
TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 98
TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 98
TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 100
TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035
(USD MILLION) 101
TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 102
TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 103
TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 105
TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 105
TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 105
TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 106
TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 106
TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 106
TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION) 107
TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION) 107
TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 107
TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED 112
TABLE 98 ACTYLIS: PRODUCT OFFERED 115
TABLE 99 ACTYLIS: PRODUCT OFFERED 115
TABLE 100 CHIRACON GMBH: PRODUCT OFFERED 118
TABLE 101 CODEXIS, INC.: PRODUCT OFFERED 121
TABLE 102 CODEXIS, INC.: PRODUCT OFFERED 121
TABLE 103 ARKEMA S.A.: PRODUCT OFFERED 125
TABLE 104 LONZA GROUP AG: PRODUCT OFFERED 128
TABLE 105 LONZA GROUP AG: PRODUCT OFFERED 128
TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED 132
TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED 132
TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED 136
TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED 136
TABLE 110 CATALENT, INC.: PRODUCT OFFERED 139
TABLE 111 CATALENT, INC.: PRODUCT OFFERED 139
TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED 143
TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED 143
LIST OF FIGURES
FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT 23
FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035) 41
FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035) 43
FIGURE 4 SUPPLY CHAIN ANALYSIS 46
FIGURE 5 PORTER’S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET 48
FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE) 51
FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE) 53
FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE) 55
FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE) 58
FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS 59
FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 60
FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 61
FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 61
FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 62
FIGURE 15 EUROPE MARKET: SWOT ANALYSIS 65
FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 66
FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 67
FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 68
FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 69
FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS 77
FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 78
FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 79
FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 80
FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 81
FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS 90
FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 91
FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 92
FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 93
FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 94
FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS 99
FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 100
FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE) 101
FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE) 102
FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE) 103
FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE) 104
FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024 109
FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET 110
FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS 112
FIGURE 39 ACTYLIS: SWOT ANALYSIS 116
FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS 118
FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS 122
FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS 125
FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS 129
FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS 133
FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS 137
FIGURE 46 CATALENT, INC: SWOT ANALYSIS 140
FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS 144
Market Research Future（マーケットリサーチフューチャー）はインドに主拠点を置き、技術的および経済的進歩に関して貴重な分析とデータを提供しています。調査結果にはMarket Research Futureのアナリストが直接著名な市場プレーヤーから入手した関連情報も含まれています。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
パターン1
| シングルユーザ | マルチユーザ | エンタープライズサイト |
| USD4,950 | USD5,950 | USD7,250 |
パターン2
| シングルユーザ | マルチユーザ | エンタープライズサイト |
| USD2,950 | USD3,950 | USD 5,250 |
ご購入に関するご案内
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。
- 手数料はいただいておりません。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルの閲覧・レポート内容の利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連企業除く）10名までレポートファイルのご共有可能です。
- エンタープライズワイドライセンス
- 同一企業であれば、人数無制限でレポートファイルの閲覧・レポート内容の利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
- その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
レポートの詳細、価格、購入等に関するご質問はいつでもお気軽にお問合せください。
最新調査レポート
